bivatuzumab mertansine
mAbexperimentalADC
Bivatuzumab mertansine is a combination of bivatuzumab, a humanized monoclonal antibody, and mertansine, a cytotoxic agent. It is designed for the treatment of squamous cell carcinoma. — Wikipedia
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2002 (NCT02254018)
Timeline
2000s
- Jan 1, 2002
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- CD44 antigenBINDING AGENT
CD44 binding agent
Specific to variant exon 6-containing CD44
- CD44 antigenINHIBITOR
CD44 inhibitor
- TubulinINHIBITOR
Tubulin inhibitor
- Tubulin beta-4B chain (TUBB4B) ↗
- Tubulin beta-1 chain (TUBB1) ↗
- Tubulin alpha-3C chain (TUBA3C) ↗
- Tubulin alpha-4A chain (TUBA4A) ↗
- Tubulin beta-3 chain (TUBB3) ↗
- Tubulin alpha-1A chain (TUBA1A) ↗
- Tubulin beta-4A chain (TUBB4A) ↗
- Tubulin beta-8 chain (TUBB8) ↗
- Tubulin beta chain (TUBB) ↗
- Tubulin alpha-1B chain (TUBA1B) ↗
- Tubulin alpha-1C chain (TUBA1C) ↗
- Tubulin alpha-3E chain (TUBA3E) ↗
- Tubulin beta-2A chain (TUBB2A) ↗
- Tubulin beta-2B chain (TUBB2B) ↗
- Tubulin beta-6 chain (TUBB6) ↗
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
- Payload
- maytansinoid
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaBivatuzumab mertansine ↗
- ChEMBLCHEMBL2109288 ↗
Also known as
- bivatuzumab mertansine
- bivatuzumab mertansine
- bivatuzumab mertansine
- biwa-1-dm1
- biwi 1 compound
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02254044 | Phase 1 | Oct 1, 2003 | Boehringer Ingelheim |
| NCT02254031 | Phase 1 | Jul 1, 2003 | Boehringer Ingelheim |
| NCT02254005 | Phase 1 | Oct 1, 2002 | Boehringer Ingelheim |
| NCT02254018 | Phase 1 | Sep 1, 2002 | Boehringer Ingelheim |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Boehringer Ingelheim | For profit | 4 | 4 | 1 | 2002 |
1 organizations
Page 1 / 1